A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors.

Trial Profile

A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2012

At a glance

  • Drugs Firtecan pegol (Primary)
  • Indications Neuroblastoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jun 2012 Primary endpoint 'Recommended-phase-II-dose' has been met.
    • 19 Jun 2012 Results have been presented at the 2012 Advances in Neuroblastoma Research Conference according to an Enzon Pharmaceuticals media release. Results were also summarised in the media release.
    • 07 Mar 2012 Planned End Date changed from 1 Jul 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top